Enhancement in the levels of neurotransmitters (norepinephrine, dopamine, 5-hydroxytryptamine, and 5-hydroxyindole acetic acid) with down-regulate the expression of AD-related intracellular markers (Tau and Aβ1−42). Here, MAPT is linked to Alzheimer disease.